Genetically modified dendritic cell (DC) vaccines expressing tumor-associated antigens are currently used for cancer immunotherapy. Peripheral blood (PB) monocyte precursors are a relatively convenient source of DCs for use in clinical studies, but are often contaminated by lymphocytes. The current study was conducted to examine the impact of Tlymphocyte contamination on genetically modified DC product. PB monocyte-derived DCs were efficiently transduced (75-95%) with an HIV-1-based self-inactivating lentiviral vector encoding a model antigen, the enhanced green fluorescent protein (eGFP). The lymphocyte-free DC culture transduced with Lenti-eGFP showed stable expression of eGFP without measurable decline in viability. In contrast, the eGFP-positive DCs disappeared rapidly in transduced DC cultures containing lymphocyte contaminants, concurrent with detectable activation and expansion of T-lymphocytes. Upon antigen recall, these T cells elicited major histocompatability complex-restricted antigen-specific cytotoxicity against eGFP-positive autologous DCs and mitogen-stimulated T lymphoblasts, mainly through the perforin-mediated pathway. In summary, this study demonstrate that the relative purity of DC cultures could determine the persistence of gene-modified DC, which may affect the induction of effective immune responses by DC vaccination strategies. Gene Therapy (2005) 12, 259-271.
Introduction
Development of immune responses to tumor cells is pivotal for the success of cancer immunotherapy. Dendritic cells (DCs) are the most potent professional antigen-presenting cells, which can induce and regulate immune responses to tumors and infectious diseases. 1 In tumor-bearing hosts, antitumor immunity can be compromised because tumor antigens fail to elicit immune mechanisms to resist tumor growth. Strategies to vaccinate against tumor-associated antigens (TAA) utilizing DC are being developed to bolster antitumor immunity. DCs can be manipulated ex vivo, and applied as a vaccine to induce antitumor immune responses in humans (reviewed by Cranmer et al 2 ). Standard approaches of ex vivo manipulation of DC include antigen pulsing (peptides, proteins, tumor cell lysates, or apoptotic/necrotic tumor cells) [3] [4] [5] or fusion to tumor cells. 6 Recently, therapeutic vaccination with genetically modified DCs expressing TAA or viral antigens has been shown to be an efficient strategy to induce immunity against malignancy and infectious diseases. [7] [8] [9] [10] [11] Genetic modification of DC with TAA genes could allow stable antigen expression as well as presentation of multiple and cryptic epitopes by both major histocompatability complex (MHC) class I and class II molecules. 11, 12 In general, DCs are generated ex vivo either from CD34 + progenitor cells or peripheral blood (PB) monocytes by culturing them in culture medium containing a defined cytokine cocktail. [13] [14] [15] Although interesting clinical data have been documented with CD34 + progenitorderived DCs, 16 collection of CD34 + cells is difficult and requires administration of granulocyte colony-stimulating factor (G-CSF). In addition, DCs generated from PB monocytes are more homogeneous and fully differentiated than that derived from CD34 + progenitors. . Monocytes are routinely obtained either by plastic adherence or by immunomagnetic selection of CD14 + cells from PB mononuclear cells. [13] [14] [15] 17, 18 However, the resulting monocyte preparations have been shown to contain variable numbers of contaminating lymphocytes. [17] [18] [19] Recently, it has been documented that DCs undergo rapid apoptosis during antigen-specific interaction with T cells both in vitro 20 and in vivo. [21] [22] [23] [24] Several studies have shown that genetically modified DCs expressing TAA could effectively process and present antigenic peptides to T cells and trigger cytotoxic response against tumor cells expressing the target antigen. 12, 25 It is important to consider that the TAA-modified DCs would also become a potential target and are at risk of being eliminated by the effector T cells they have activated. Therefore, T-cell contamination in DC cultures may pose a potential obstacle to the persistence of genetically modified DCs and limit their capacity to prime cytotoxic T-lymphocyte (CTL) immunity.
To examine this issue, in the present study DC cultures were generated from PB monocytes containing significant numbers of contaminating lymphocytes and relatively pure population of CD14 + cells obtained by plastic adherence and immunomagnetic selection procedures, respectively. We transduced them with a HIV-1-based self-inactivating (SIN) lentiviral vector expressing a widely used reporter molecule, the enhanced green fluorescent protein (eGFP). Previously, it has been shown that eGFP is immunogenic in human, 26 non-human primates 27, 28 and in murine models. 29, 30 Evidences also suggest immune rejection of transplanted eGFP-positive cells in non-human primate recipients in myeloablative 27 as well as nonablative settings. 28 Hence, using eGFP as a model antigen, herein we show that Lenti-eGFP-transduced DC could effectively process and present the eGFP-derived antigenic peptides to contaminating lymphocytes in DC culture and reproducibly generate CTLs capable of eliminating the eGFP-expressing DCs. These studies provide direct evidence on the efficiency of genetically engineered DCs in inducing antigen-specific immune responses and demonstrate the impact of lymphocyte contamination on genetically modified DCs expressing immunogenic proteins.
Results

Generation of monocyte-derived DCs
To generate DCs, monocytes were isolated from Peripheral blood mononuclear cells (PBMCs) of normal donors (n ¼ 5) by plastic adherence (monocytes: B84%, range 71-92% and lymphocytes: B18%, range 8-29% ) and typical morphology of DCs, irrespective of the presence (DC culture-1) or absence (DC culture-2) of contaminating lymphocytes in cultures ( Figure 1 ).
Lentivirus transduction of monocyte-derived DCs
Transduction of DC cultures with Lenti-eGFP vector enabled direct monitoring of transduction efficiency and gene expression by flow cytometry. After 48 h transduction with concentrated Lenti-eGFP vector particles (multiplicity of infection (MOI) B10), cells were washed and cultured in fresh DC culture medium containing GM-CSF and IL-4 in the presence or absence of DC maturation agents tumor necrosis factor (TNF)-a and soluble CD40L (sCD40L), and analyzed periodically for viability, phenotype, and eGFP expression.
As represented in Figure 2 , an average of 85% (range 74-96%) and 88% (range 70-98%) of CD11c + /HLADR + DCs showed eGFP expression in DC culture-1 containing lymphocyte contaminants and lymphocyte-free DC culture-2, respectively, at 48 h after transduction. At this Figure 1 Phenotypic analysis of day 4 immature DCs derived from PB monocytes with or without lymphocyte contaminants. Immature DCs were generated from normal human PB monocytes by plastic adherence (DC culture-1) or immunomagentic selection (DC culture-2). On day 4, DCs were stained with mAbs against DC cell surface markers or appropriate isotype control antibody (IsoAb) as described in Materials and methods. Expression of indicated surface markers was evaluated on cells positive for the expression of HLA-DR antigen and negative for lineage markers (CD3, CD14, CD19, and CD56) in the gated cell population possessing high scatter property represented in scatter diagrams. Figure 3, top row) . Furthermore, the lymphocyte contaminants in DC cultures were also transduced by the Lenti-eGFP vector particles as depicted in Figure 3 (top row). However, despite high transduction efficiency, the level of eGFP expression was low in both the DC and lymphocyte cell populations at this early time point (Figure 3 , top row), but increased upon extended culture ( Figure 3 , middle and bottom rows). Notably, the mean fluorescence intensity (MFI) of eGFP expression was further increased both in transduced DC and lymphocytes after TNF-a and sCD40L stimulation ( Figure 4) . The enhanced transgene expression detected in DCs following stimulation with TNF-a Immune responses to gene-modified dendritic cells N Chinnasamy et al and sCD40L correlated with their terminal differentiation as assessed by further upregulation of costimulatory molecules (CD80, CD86, CD40, and CD54) and MHC molecules, and also by expression of maturation marker CD83 (data not shown) as suggested previously. 31 Similarly, increased expression of eGFP in transduced lymphocytes contaminants after exposure to TNF-a and sCD40L might be due to changes in their activation status, probably by receiving costimulatory and immunostimulatory factors from mature DCs due to the direct effect of TNF-a and sCD40L.
Elimination of transgene-positive cells from DC cultures transduced with Lenti-eGFP: impact of lymphocyte contamination Next, we assessed the impact of lymphocyte contamination on the survival of gene-modified DCs in the presence or absence of DC maturation signals TNF-a and sCD40L. As shown in Figure 3 , no detectable loss of eGFP + DCs was noticed for up to 6 days of culture following transduction in immature DC cultures, irrespective of the presence (Figure 3 , left) or absence ( Figure  3 , right) of lymphocyte contaminants. In contrast, a progressive decline in eGFP + DCs was reproducibly demonstrated in DC culture-1 containing contaminating lymphocytes that were matured with TNF-a and sCD40L. Concomitant to that rapid expansion of lymphocyte fraction was consistently documented in these cultures. Contrary to these results, DC culture-2 not containing T cells but similarly matured with TNF-a and sCD40L showed no or very low decline in eGFP + DCs at comparable time points (Figure 4 , right). Notably at the end of 7 days post-transduction, eGFP + DCs were rarely detectable (B1%, range 0.5-1.5%) in Lent-eGFP-transduced mature DC culture-1 containing lymphocytes (Figure 4 , left) and the cultures were predominantly populated with lymphocytes morphologically resembling activated lymphoblasts (Figure 5a) .
These results clearly demonstrate that the disappearance of eGFP + DCs in transduced DC cultures was directly associated with the presence of T-cell contaminants and TNF-a-and sCD40L-mediated maturation of DCs rather than eGFP-induced toxicity. A total of five samples from independent donors have been studied with similar results.
Characterization of T-lymphocyte contaminants that were expanded during gene-modified DC cultures matured with TNF-a and sCD40L
The results from the preceding experiments suggest that gene-modified DCs matured with TNF-a/sCD40L acquired efficient antigen-presenting and T-cell stimulatory Figure 3 Lentivirally transduced immature DCs could survive and stably express the transgene irrespective of the presence or absence of lymphocyte contaminants. Immature DCs were generated from PB monocytes with (DC culture-1) or without (DC culture-2) lymphocyte contaminants and transduced with Lenti-eGFP vector as described in Figure 2 . After transduction, cells were washed and cultured in DC medium containing GM-CSF (500 U/ml) and IL-4 (500 U/ml), and analyzed for eGFP expression by flow cytometry at the indicated time points. Same side scatter and FL1-H settings were used to analyze both DCs and lymphocytes. As the nonactivated lymphocytes were smaller than DCs, the autofluorescence of untransduced cells was comparatively lower than that of DCs, and thus are not noticeable in the dot plots. Hence, eGFP expression in DC (large cells) and lymphocyte (small cells) populations were determined using gates that were set relative to respective cell populations of untransduced control cultures. Percentages of eGFP + cells are indicated. Data are a representative of five experiments.
Immune responses to gene-modified dendritic cells N Chinnasamy et al functions, and effectively induced effector T cells with cytotoxicity against transgene-positive cells in culture. To test our hypothesis, lymphocytes from both untransduced and Lenti-eGFP-transduced DC culture-1 that were matured with TNF-a and sCD40L were harvested at 7 days post-transduction, and expanded ex vivo in medium containing IL-2 and IL-7 as described in Materials and methods. Cells were characterized for immunophenotype and activation status before and after ex vivo culture. As shown in Figure 5b before ex vivo expansion in medium containing low-dose IL-2 and IL-7, the lymphocytes derived from both untransduced and Lenti-eGFPtransduced mature DC culture-1 comprised predominantly by CD3 + T cells (X99%). Further, no preferential growth or expansion of CD4 + versus CD8 + T cells was documented in lymphocytes obtained from untransduced mature DC culture-1, which comprised B65% (range 55-70%) CD3 
Detection of eGFP-specific cytotoxic effector T cells
The reproducible loss of transgene eGFP + cells in genemodified, TNF-a and sCD40L matured DC culture-1 containing lymphocytes, prompted us to examine whether induction of CTL response against eGFP might Figure 4 Kinetics of disappearance of eGFP-expressing cells in Lenti-eGFP-transduced DC culture matured with TNF-a and sCD40L. Immature DCs were generated from PB monocytes with (DC culture-1) or without (DC culture-2) lymphocyte contaminants and transduced with Lenti-eGFP vector and cultured as described in Figure 3 . After transduction, cells were washed and cultured in DC culture medium containing GM-CSF and IL-4 (each at 500 U/ ml) in the presence of DC maturation agents TNF-a (10 ng/ml) and sCD40L (500 ng/ml), and analyzed for eGFP expression by flow cytometry at the indicated time points as described in Immune responses to gene-modified dendritic cells N Chinnasamy et al have contributed to the disappearance of eGFP + cells. To test this, lymphocyte contaminants obtained from untransduced and transduced mature DC culture-1 and expanded in vitro in medium containing IL-2 and IL-7 for 7 days were examined for cytotoxicity against eGFP + autologous target cells.
In the preceding experiments with primary DC cultures, we observed a relatively different kinetics of cytotoxicity against transgene expressing DCs and lymphocytes as described earlier, possibly because of the differences in their antigen processing capacity or level of expression of accessory and MHC molecules. Hence, we prepared lymphocyte-free autologous DCs and phytohemagglutinin (PHA)/IL-2-stimulated T lymphoblasts and transduced them with lentiviral vector expressing eGFP or LacZ. Over 90% of transduced DC and T lymphoblast target cells expressed eGFP (B92%, range 90-96%) or LacZ (B90%, range 88-95%) after 48 h post-transduction. Cells were labeled with 51 Cr, and then used as target cells in cytotoxicity assays. The results of one representative experiment conducted with three different samples are presented in Figure 7 . As shown in Figure 7a , the cytotoxic assays using effector cells obtained from eGFP-transduced mature DC cultures elicited strong lytic activity specific for autologous eGFP + DCs, but failed to lyse untransduced control or an alloantigen (LacZ)-expressing DC. Similar results were observed when we used PHA/IL-2-stimulated autologous lymphoblasts as targets in all the three samples (obtained from different donors) studied ( Figure  7b ). In contrast, effector T cells obtained from untransduced DC cultures were unable to lyse any of the target cells tested. Similarly, no cytolytic activity was observed with any of the effector cells against NK-sensitive target cells K562 (data not shown). Taken together, these results suggest that eGFP + cells could be specifically recognized by effector T cells and the loss of eGFP + cells in transduced DC cultures containing lymphocytes was indeed due to cell-mediated immune response.
MHC restriction of eGFP-specific CTLs
To determine the MHC restriction of eGFP-specific effector T cells, we studied the inhibitory effect of anti-MHC antibodies on their cytolytic activity. As depicted in Figure 7c , blocking of MHC class-I but not of MHC class-II molecules of the target cells significantly inhibited (B80%, range 75-82%) the cytotoxicity of the eGFPspecific effector CTLs. A combination of anti-MHC class-I and class-II antibodies produced a synergistic (X90%, range 85-95%) inhibitory effect on cytotoxicity against eGFP + autologous DCs (Figure 7c ). These results further confirmed that the immune epitopes within eGFP were presented mostly in association with MHC class I and to a lesser extent with class II molecules. Consistent with these findings, flow cytometry analysis showed that the effector cells consisted of approximately B72% (range 68-75%) CD3 + CD8 + cytotoxic T cells and B28% (range 24-32%) CD3 + CD4 + helper T cells.
The perforin exocytosis pathway mediates eGFPspecific cytotoxic T-cell response
To investigate whether the FasL/Fas or perforin systems mediated the cytotoxic function of eGFP-specific effector cells, we examined the effect of concanamycin A (CMA) and Brefeldin A (BFA), selective inhibitors of perforinand Fas-mediated cytotoxicity, respectively. As depicted 
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in Figure 7d , treatment of the effector cells with BFA induced B22% (range 11-24%) inhibition in the lytic activity of eGFP-specific effector cells, indicating that the Fas/FasL system was not the main pathway of cytotoxicity. In contrast, when we studied the inhibition of cytotoxicity by pretreatment with CMA, almost 86% (range 81-90%) of cytolytic activity was abrogated. Treatment of BFA or CMA itself did not have any growth inhibitory or cytotoxic effects on target and effector cells (data not shown). These results indicate that mainly the perforin-dependent pathway mediated the cytotoxic function of eGFP-specific effector T cells.
Discussion
Development of genetically modified DC vaccine expressing antigens is an innovative immunotherapy strategy for the treatment of malignancy and other infectious diseases. In general, DCs generated from adherent celldepleted PB monocytes are used for the development of gene-modified DC vaccines that express known tumor antigens, using either non-viral or viral vectors. 7, 9, 10, [31] [32] [33] We, and others, have shown the potential of HIV-1-based lentiviral vectors in delivering transgene to human monocyte-derived DCs and the induction of T-cell responses. 25, [34] [35] [36] The initial aim of the current study was to develop and optimize a clinically feasible method to generate gene-modified DC vaccines using an SIN lentiviral vector for cancer immunotherapy. Similar to previous findings, 37, 38 the current study demonstrate that the SIN lentiviral vector could reproducibly transduce PB monocyte-derived immature DCs, resulting in the high level of transgene expression. However, we provide evidence that the relative purity of DC cultures could determine the survival of gene-modified DCs. Figure 7 Cytotoxicity of effector T cells generated in Lenti-eGFP-transduced DC cultures against eGFP + autologous target cells. Lymphocyte contaminants from untransduced and Lenti-eGFP-transduced mature DC culture-1 generated using three different donors were harvested at 7 days post-transduction and expanded as described in Figure 6 . Cultures were tested for eGFP-specific cytotoxicity against autologous DC (a) and PHA-stimulated T lymphoblast (b) target cells transduced with Lenti-eGFP ('), Lenti-LacZ (K), or untransduced control (m) at various effector/target ratios by a standard chromium ( 51 Cr) release assay. The results are presented as the mean of triplicate wells at each effector/target ratio. In each panel, the last graph shows the mean7s.e.m. values of data from three different donor samples. In some cytotoxicity assays, the effector cells were tested for CTL activity against eGFP + autologous DCs (effector/target ratio of 50:1) in the presence of antibodies against MHC class I, class II, both, or matched IsoAb (c), or in the presence of CMA or BFA (d). Results are expressed as the mean7s.e.m. of three independent experiments using samples from three different donors.
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As reported previously, 37 after 48 h of transduction with concentrated SIN Lenti-eGFP vector particles (MOI B10), B90% of the immature DCs expressed eGFP, irrespective of the purity of monocytes used to generate DC cultures. Furthermore, no significant decline in either eGFP expression or viability of eGFP + DCs was documented in lentivirally transduced immature DC cultures for up to 6 days after transduction, irrespective of the presence or absence of lymphocyte contaminants (Figure 3 ). However, a rapid and progressive loss of eGFP + DCs and lymphocytes was consistently observed in gene-modified DC cultures containing high number of lymphocyte contaminants that were matured with TNF-a and sCD40L following transduction (Figure 4, left) . In contrast, Lenti-eGFP-transduced DC culture-2 that were established with relatively pure monocytes and matured similarly with TNF-a and sCD40L showed little or no loss of eGFP + DCs when analyzed at comparable time points (Figure 4, right) . These results show that neither vector components including VSV.G-related toxicity nor high-level expression of eGFP had negative impact on survival of transduced DCs. However, it strongly suggests that induction of immune response to lentivirally transduced cells, possibly due to the presentation of one or more of immunogenic antigens to contaminating T cells by LentieGFP-transduced DCs upon TNF-a-and CD40L-induced maturation.
A potential immunogen could be the VSV.G envelope protein 39 that was used to pseudotype the lentiviral vector particles. However, in the current study the VSV.G glycoprotein was produced only during virus production by the transiently transfected 293T cells and not in transduced target cells. One could argue that VSV.G protein could be taken up by DCs during transduction procedure and generate an immune response. However, the effector T cells obtained from Lenti-eGFP-transduced DC cultures did not lyse any of the target cells transduced with VSV.G-pseudotyped lentiviral vector expressing an alloantigen LacZ, which confirms that immune response to VSV.G did not contribute to the disappearance of gene-modified DCs. In addition, in antigen recall cytotoxicity assays, the T cells obtained from eGFP-modified mature DC cultures elicited a strong and specific cytotoxic response against both eGFP + autologous DCs (Figure 7a ) and lymphoblasts ( Figure 7b ) in an MHC class-I restricted manner.
Contrary to these cytotocixity assay results obtained with effector cells from Lenti-eGFP-transduced mature DC culture-1 that were expanded for a short period in the presence of IL-2 and IL-7 (Figure 7) , the lymphocyte contaminants of primary mature DC culture-1 at 7 days post-transduction mostly contained CD4 + and B24-32% CD4 + T cells) survived at the end of ex vivo culture in medium containing IL-2 and IL-7 ( Figure 6 ).
In general, DCs have been shown to express high level of MHC class II, in addition to class I molecules, 40 and T cells express the MHC class I molecules constitutively 41 and MHC class II molecules upon activation 42 on their cell surface. Both CD4 + and CD8 + T-cell-mediated killing of cognate APC populations including DCs, B cells, and macrophages has been reported in several studies [20] [21] [22] [23] [43] [44] [45] and was shown to be mediated via Fas ligand (FasL)-dependent 20, [46] [47] [48] or -independent mechanisms. 23, 44 Similarly, CD8 + CTL-mediated elimination of transplanted neo-antigen-positive T cells and other hematopoietic cells has been previously demonstrated in vivo both in animal models [27] [28] [29] and humans. 49 In vitro killing of target cells by CD8 + CTLs is mediated primarily by the perforin pathway and to a lesser extent via FasL/Fas interactions, whereas CD4 + T-cell cytotoxicity is conducted essentially by the Fas pathway. 50 Hermans et al 21 demonstrated a specific and rapid CTLmediated elimination of antigen-loaded DCs in draining lymph nodes of TCR transgenic mice. However, the mechanisms that lead to DC elimination have not been defined in this study. The present study demonstrates that the cytotoxicity against eGFP-expressing DCs and lymphoblasts in vitro was mediated mainly through perforin pathway and to a lesser extent by FasL (Figure 7d) .
Collectively, our findings suggest that induction of Tcell-mediated immune response against eGFP was responsible for the elimination of gene-modified DCs and indicate that combination of T-cell contamination and TNF-a/CD40L-mediated DC maturation is required for rapid induction of immune effector cells and elimination of target antigen-expressing cells. Supporting our data, previously it has been shown that peptides derived from eGFP degradation are immunogenic in rodents, non-human primates, and humans. [26] [27] [28] [29] [30] As a consequence, survival of eGFP gene-modified cells was reduced or completely abrogated in transplanted animals. [27] [28] [29] [30] Furthermore, similar to our findings, other reports suggest that immunostimulatory properties of DCs are linked to their maturation state. Systemic expression of antigens on nonprofessional or immature DCs render naïve T cells unresponsive, whereas T-cell responses are rapidly promoted when antigen is presented by mature DCs or in an environment that leads to the activation of DCs. 51, 52 Some may argue that the CTL expansion and cytoxicity we observe is simply too rapid to be antigen specific and that what we observe is possibly nonspecific killing or NK-cell activity. Yet, our CTL assays show strong antigen specificity and MHC class I restriction, and our cultures contained no NK cells. Rapid induction of CTL response from naïve T-cell precursors after stimulation with neo-or self-antigen-loaded DC is not a new finding and has been demonstrated previously in several studies. [53] [54] [55] We believe it likely that there are multiple reasons for the rapid induction of CTL response
+ DCs in our DC culture system. One reason is the high transduction frequency of DCs and transgene expression we have observed (B90%) with Lenti-eGFP vector. The increased expression of CD80, CD86, MHC molecules, and adhesion molecule CD54 by TNF-a and sCD40L matured DCs may also contribute to generating the robust CTL response.
Another strong possibility may be the existence of one or more eGFP peptide sequence with homology to a potential common microbial or self-peptide sequence resulting from molecular mimicry and reactivation of existing crossreactive CTL precursors. Several lines of evidence suggest that imprinting of the memory T-cell repertoire can occur during primary microbial infection and remain stable over time and could be reactivated rapidly by crossreactions involving apparently completely unrelated self, bacterial, or other foreign peptide analogs resulting from molecular mimicry. 56, 57 In support of our speculation, recently Bhattacharya et al 58 have reported the existence of partial crossimmunity between eGFP and tumor antigen Her2/neu, and demonstrated that the rejection of Her2/neu-expressing tumors in eGFP vaccinated animals by both cell-mediated and humoral immune responses. However, further studies are required to facilitate a deeper understanding of this mechanism.
Collectively, the current study documents the efficiency of lentivirally transduced mature DCs in generating strong immune response against transgene product and also provides evidence on the potential use of genetically modified DC vaccines for immunotherapy of cancer and other infectious diseases. To our knowledge, this is the first demonstration of the negative impact of lymphocyte contamination on the persistence of genetically modified DC expressing a highly immunogenic antigen. Our findings suggest that in a clinical setting, vaccination with immunogenic TAA expressing mature DC preparations containing contaminating T cells may result in rapid elimination of the transgene-positive DCs before reaching the secondary lymphoid organs to induce further expansion of specific T-cell precursors. This may seriously limit the capacity of DC vaccines to induce effective immune responses in vivo. However, it could be used as an ex vivo platform to generate and expand large number of antigen-specific T cells for adoptive immunotherapy. Additionally, here we show that DC cultures generated from relatively pure monocytes could stably express the transduced antigen without decline in viability and thus represent an ideal method for the generation of gene-modified DC vaccines for immunotherapy applications.
The results of the current study with eGFP as an immunogenic transgene product in DCs might not be directly extrapolated to conditions involving weakly immunogenic TAA, because the kinetics of induction of CTL response to DC expressing a TAA with weak immunogenicity may be comparatively slow or low. However, caution should be exercised if such DC vaccines are used in combination with other biological or molecular strategies that are expected to increase its immunogenicity. Currently, studies are in progress to determine the efficiency of lentivirally modified DCs expressing TAA carcinoembryonic antigen or prostatespecific membrane antigen, using similar DC culture system.
Materials and methods
Isolation of monocytes from PB buffy coat
PBMCs were isolated from buffy coat obtained from five healthy donors (Blood Transfusion Center, Milwaukee, WI, USA) by density-gradient centrifugation over FicollPaquet Plus (Amersham Biosciences AB, Uppsala, Sweden). Aliquots of PBMCs were cryopreserved in liquid nitrogen until use. To obtain CD14 + monocytes, the cryopreserved PBMCs were thawed and plated in 75 cm 2 tissue culture flasks (Falcon, Becton Dickinson Labware, Franklin Lakes, NJ, USA) at 5 Â 10 6 cells/ml in a total volume of 10 ml OptiMEM-1 (Gibcot, Invitrogen Corp., Grand Island, NY, USA) containing 5% pooled human AB serum (HS; BioWhittaker, Walkersville, MD, USA) and 10 U/ml of DNase-I (Sigma, St Louis, MO, USA), and incubated at 371C 5% CO 2 for 2-3 h to allow cell adhesion. The adherent monocytes were collected after removing the nonadherent cells by extensive washings with phosphate-buffered saline (Invitrogen Corp) and used directly to generate DCs (DC culture-1). In parallel, half of the adherent monocytes were further enriched for CD14 + monocytes by depleting the residual lymphocytes (CD2, CD7, CD16, CD19, and CD56) using Monocyte Negative Isolation kit (Dynal Biotech Inc., Lake Success, NY, USA) according to the manufacturer's instructions and then differentiated into DCs (DC culture-2). The purity of the monocytes was determined by immunostaining with mouse monoclonal antibodies (mAbs) against human blood cell lineage markers CD14, CD3, CD19, and CD56, followed by flow cytometry. In order to generate lymphocyte-free DC cultures, the purified CD14 + monocyte fractions were discarded if base line contaminating lymphocytes made up X1%.
Generation of DCs
To generate immature DCs, the monocytes were plated at 1 Â 10 6 cells/well in six-well plates (Coster s , Corning Inc., Corning, NY, USA) containing 2 ml/well DC culture medium (OptiMEM-1 containing 5% HS) supplemented with 500 U/ml of recombinant human (rh) cytokines GM-CSF and interleukin (IL)-4 (both from R&D Systems, Minneapolis, MN, USA). Cells were cultured for 4 days at 371C in 5% CO 2 and 95% humidity, phenotypically characterized and used in subsequent experiments as described below.
Plasmids and lentiviral vector production
The plasmids used in this study were as follows: the HIV-1-based gene transfer vectors pRRLsin18.PPT.hPG-K.eGFP.Wpre and pRRLsin18.PPT.hPGK.LacZ.Wpre (hereafter referred as Lenti-eGFP and Lenti-LacZ respectively), the vesicular stomatitis virus G protein (VSV-G) envelope encoding construct pMD.G, and the packaging construct pCMV DR8.91 were kindly provided by Dr D Trono, Department of Genetics and Microbiology, CMU, Geneva, Switzerland. The lentiviral vector particles were produced in 293T cells (American Type Culture Collection, Manassas, VA, USA) by three-plasmid transfection using a calcium phosphate transfection kit (Invitrogen) as described previously, 34, 59 except that Opti-MEM-1 containing 5% HS was used as culture medium. The viral supernatants were concentrated to 50 Â by ultracentrifugation (50 000 g, 1.5 h, 41C). Viral pellets were resusImmune responses to gene-modified dendritic cells N Chinnasamy et al pended in Opti-MEM-1 and stored frozen at À801C until use. The titer of the viral preparations and the presence of replication-competent lentivirus (RCL) were determined as described previously. 34, 59 No RCL was detectable in any of the vector preparations used in this study.
Lentiviral transduction of DCs
Immature DC cultures (day 4) were transduced with lentiviral vectors at an MOI of 10, in the presence of protamine sulfate (5 mg/ml, Sigma), in six-well plate containing 2 ml/well of DC culture medium supplemented with GM-CSF and IL-4. After 48 h transduction, cells were washed and cultured in fresh DC culture medium containing GM-CSF (500 U/ml) and IL-4 (500 U/ml) in the presence or absence of 10 ng/ml of TNF-a (PeproTech, Rocky Hill, NJ) and 500 ng/ml of soluble CD40 ligand (sCD40L, Serotec Inc., Raleigh, NC, USA) for various lengths of time before the indicated parameters were measured. The viability of DC cultures was monitored periodically before and after transduction using trypan blue (Sigma) staining.
Lentiviral transduction of mitogen-activated primary human T-lymphocytes
To obtain mitogen-activated T lymphoblasts, adherent cell-depleted PBMCs were cultured in R5 culture medium (RPMI 1640 containing 5% HS and 2 mM Lglutamine) in the presence of 5 mg/ml of PHA (Sigma) and 100 IU/ml of rhIL-2 (PeproTech, Norwood, MA, USA) for 2-3 days. Lentiviral transduction of activated lymphoblasts was performed on fibronectin-coated sixwell plates (Becton Dickinson, San Jose, CA, USA) in the presence of 5 mg/ml protamine sulfate by spinoculation; cells were mixed with Lenti-eGFP or Lenti-LacZ vector particles at an MOI of B10, centrifuged at 2000 r.p.m. for 30 min at 321C, and incubated for 48 h at 371C . Following transduction, cells were washed and cultured in fresh R5 medium containing 100 U/ml of IL-2.
Flow cytometry mAbs conjugated with fluorescein isothiocyanate, phycoerythrin (PE), or peridinin chlorophyll protein were purchased from BD-PharMingen (San Diego, CA, USA). The purity of monocytes was determined by staining them with mAbs against the human blood cell lineagespecific markers CD3, CD19, CD14, and CD56, following the manufacturer's instruction. To determine the immunophenotype and maturation/activation status, cells from untransduced and Lenti-eGFP-transduced DCs cultured under different conditions were collected at various time points and stained with mAbs against cell surface markers as indicated in results. Isotype control antibodies (IsoAb) were used to assess the specificity of immunostaining. A total of 5000 to 10 000 events were acquired with a FACScan flow cytometer and CellQuestt software (Becton Dickinson, San Jose, CA, USA). T cells were analyzed by gating on small and large activated lymphocytes by forward and side scatters excluding the DCs and DC-T-cell conjugates.
Expression of eGFP and LacZ gene product bgalactosidase (b-gal) in transduced cells was determined at different time points after transduction by flow cytometry. Expression of eGFP was directly analyzed by measuring its fluorescence intensity. b-gal expression in transduced cells was determined using the ImaGene Greent C 12 FDG lacZ gene expression kit (Molecular Probes, Eugene, OR, USA) as described by the manufacturer.
Detection of eGFP-specific cytotoxic effector cells using cytotoxicity assays For antigen recall assays, contaminating lymphocytes from untransduced and Lenti-eGFP-transduced mature DC culture-1 were harvested on day 12 after culture initiation (7 days post-transduction) and viable cells were recovered by gradient centrifugation over Ficoll. Cells were then washed and cultured in fresh R5 culture medium supplemented with IL-2 (20 U/ml), and IL-7 (10 ng/ml; R&D Systems) for 7 days. Media supplemented with cytokines were replaced every 2-3 days. At the end of culture period, cells (hereafter referred as effector cells) were immunophenotyped and subjected to chromium ( 51 Cr) release assay to determine antigen-specific cytotoxicity.
Target cells included autologous DCs and PHAstimulated lymphoblasts, which were either unmodified or lentivirally transduced with Lenti-eGFP or Lenti-LacZ. The percentage of target cells expressing transgene was determined as described earlier. K562 cells were used as targets to detect NK cell activity. Target cells were labeled with sodium chromate ( To determine the MHC restriction of cytolytic activity, antibodies against MHC class I and/or class II or an isotopic control mouse IgG at 20 mg/ml (all from BD PharMingen) were added to the cultures at the initiation of CTL assay. Also to examine the mechanism of cytotoxicity of eGFP-specific CTLs, we tested the effect of CMA and BFA (both from Sigma), selective inhibitors of perforin-and Fas-mediated cytotoxicity, respectively. Effector cells were pretreated with 100 nM CMA or 10 mM BFA for 2 h and assayed for cytotoxicity as described above in the presence of the drugs.
The percent-specific 51 Cr release was calculated as: ((mean experimental c.p.m.-mean spontaneous c.p.m.)/ (mean maximum c.p.m.Àmean spontaneous c.p.m.)) Â 100%, in which spontaneous release represents c.p.m. in supernatants from wells containing target cells with medium only and maximum release represents c.p.m. in supernatants from wells containing target cells in medium with 2% Triton X-100 (Sigma). In all these cytotoxicity assays, spontaneous release of chromium was B10% (range 5-15%) of maximum release. Assay wells were run in triplicate and results are presented as the mean7s.e.m.
